Loading...
Docoh

Inhibikase Therapeutics (IKT)

News

From Benzinga Pro
Recap: Inhibikase Therapeutics Q1 Earnings
16 May 22
Earnings
Inhibikase Therapeutics (NASDAQ:IKT) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Inhibikase Therapeutics Q1 EPS $(0.18) Misses $(0.17) Estimate
16 May 22
Earnings, News
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 30.77 percent increase over losses of $(0.26) per
Earnings Scheduled For May 16, 2022
16 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Inhibikase Therapeutics's Return On Capital Employed Overview
1 Apr 22
Earnings
Inhibikase Therapeutics (NASDAQ:IKT) brought in sales totaling $1.94 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 12.76%, resulting in a loss of $5.04 million.
Inhibikase Therapeutics FY21 EPS $(0.81) Down From $(0.35) YoY, Sales $3.10M Up From $700.00K YoY
31 Mar 22
Earnings, News
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.81) per share. This is a 131.43 percent decrease over losses of $(0.35) per share from the same period last year. The company reported $3.10 million
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
31 Mar 22
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For March 31, 2022
31 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Earnings Outlook For Inhibikase Therapeutics
30 Mar 22
Earnings
Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Inhibikase Therapeutics will report an earnings per share (EPS) of $-0.17.
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
30 Mar 22
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
27 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, Trading Ideas, General
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
18 Mar 22
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
13 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Inhibikase Therapeutics To Present Phase 1/1b Clinical Data At The Upcoming AD/PD Alzheimer's & Parkinson's Diseases Conference
8 Mar 22
News, FDA, Events
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that

Press releases

From Benzinga Pro
Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
16 May 22
Earnings, Press Releases
Company to host conference call and webcast on Tuesday, May 17, 2022, at 8:00am ET BOSTON and ATLANTA, May 16, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage
Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
10 May 22
Press Releases
BOSTON and ATLANTA, May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease
Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
9 May 22
Press Releases
BOSTON and ATLANTA, May 9, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
21 Apr 22
Press Releases
BOSTON and ATLANTA, April 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease
Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity
31 Mar 22
Earnings, Press Releases
BOSTON and ATLANTA, March 31, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022
25 Mar 22
Press Releases
BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference
23 Mar 22
Press Releases
BOSTON and ATLANTA, March 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease